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Abstract
Background: The demographic composition and the frequency and nature of social contacts may affect the spread of
influenza virus in a population, resulting in distinct age-dependent immunity patterns. As demography and social
contact rates differ strongly between European countries, this may impact infection incidence and vaccine effectiveness
and thus limit the extent to which conclusions derived from observations in one country can be generalized to others.
In the current study, we aimed to decipher the impact of social contact patterns and demographic factors on simulation
results and, thus, to determine to what extent vaccination results can be generalized.
Methods: We simulated the transmission of four influenza strains (A(H1N1), A(H3N2), B/Victoria, B/Yamagata) in Belgium,
Finland, Germany, GB, Italy, Luxembourg, Netherlands and Poland, using the simulation tool 4Flu. Individuals were
connected in a dynamically evolving age-dependent contact network based on the POLYMOD study.
Results: When averaged over 20 years, simulation results without vaccination ranged from annually 20,984 (Germany) to
31,322 infections (Italy) per 100,000 individuals. QIV annually prevented 1758 (Poland) to 7720 infections (Germany) per
100,000. Variability of prevented cases remained high when the country-specific vaccination was replaced by unified
coverage, but was reduced considerably if the same demography was used for all countries, or even more so when the
same contact matrix was used.
Conclusions: Contact matrix and demography strongly influence the age-dependent incidence of influenza and the
success of vaccination. Projecting simulation results from one country to another can, therefore, lead to erroneous results.
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Background
Influenza viruses constantly change and vaccines must
be reformulated every year. As a consequence, vaccine
efficacy from previous years may not be fully applicable
for subsequent years. This problem has been recognized
and led the European Medicine Agency (EMA) to draft
guidelines for influenza vaccines (EMA/CHMP/VWP/
457259/2014) in which they request that vaccine effect-
iveness (VE) for individual influenza vaccines should
routinely be investigated. The epidemiology of influenza
should be influenced by the demographic composition of
the population and by age-dependent immunity patterns
which result from prior influenza waves. The frequency
and nature of social contacts is also likely to affect the
spread of infections in a population. Contact patterns and
rates strongly differ among European countries, and this
may limit the extent to which modeling results obtained
from one country can be generalized. A population-based
prospective survey showed that age dependent contact
patterns are highly assortative with age [1]. In all coun-
tries, the average contact rates (i.e. the number of contacts
per individual per day) strongly varied among age groups,
usually peaking for juveniles. Furthermore, contact rates
averaged over all ages differ substantially between coun-
tries (Italians report the highest, Germans the lowest
rates). Many European countries are currently experien-
cing substantial demographic changes (generally, declining
birth rates and increasing life expectancy lead to ageing
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populations), yet demographic projections indicate that
these changes occur at very different pace in the European
countries [2]. Specifically, as children and juveniles con-
tribute most to the spread of influenza [3], these demo-
graphic changes may further limit extrapolations from one
country to others.
We examined the influence of contact patterns and
demography on the epidemiology of influenza by using
the previously published tool 4Flu which simulates the
simultaneous and independent transmission of four influ-
enza strains (A(H1N1), A(H3N2), B/Victoria, B/Yamagata)
in a population with demographic turnover [4, 5]. Individ-
uals were connected in a dynamically evolving age-
dependent contact network based on the contact structures
which were determined in the EU POLYMOD study [1].
Mathematical modeling of infectious diseases can help
to assess the impact of preventive interventions such as
vaccination and increasingly informs public health deci-
sions in this field. Mathematical models influenced the
UK’s decision to extend the annual influenza vaccination
program to children [6, 7]. They also supported the rec-
ommendations to introduce rotavirus vaccination in the
childhood vaccination calendar of Germany and human
papilloma virus vaccination in Denmark [8, 9]. Mathem-
atical modeling may also help to optimize strategies for
influenza vaccine effectiveness assessment. In the current
study, we aimed to decipher the impact of social contact
patterns and demographic factors on simulation results
and, thus, to determine to what extent vaccination results
can be generalized. We used a version of 4Flu which has
been extended to allow for using demographic data and
contact structures of different countries to explore for
all eight European countries which participated in the
POLYMOD study the influence of contact pattern and
demographic changes on the simulation outcomes.
Methods
We used a modified version of the previously published
individual-based simulation tool 4Flu [4, 5] which extends
the standard susceptible-infected-resistant (SIR) model by
including maternal protection, loss of immunity, boosting
infections and vaccinations Fig. 1; 4Flu is freely available
for download [10]. For a list of modeling parameters, see
Additional file 1: Table S1.
Initialization and evaluation period
Each simulation ran for 40 years: during the first 20 years
(starting on July 1st 1994), the age-dependent immunity
pattern of the population was initialized by applying tri-
valent influenza (TIV) vaccinations (using the recorded
vaccination coverage and the B lineage which actually was
contained in TIV) and allowing for independent trans-
mission of four influenza strains A(H1N1), A(H3N2),
B/Victoria and B/Yamagata in populations with demographic
turnover. In 2014, a 20 year evaluation period started
during which all TIV vaccinations were replaced by
vaccination with tetravalent influenza vaccine (QIV)
which contained both B lineages. During the evaluation
period, the number of cases was reported on a daily
basis.
Demographics
We applied this study to each one of the eight countries
for which contact structures were determined in the
POLYMOD project: Belgium, Finland, Germany, Great
Britain, Italy, Luxembourg, the Netherlands, and Poland
[1]. For each country, the official demographic age distri-
butions from 1994 to 2033 were used (Fig. 2); data were
obtained from Deutsches Statistisches Bundesamt [11]
for Germany and from the Eurostat web pages [12] for
the other countries. Age-dependent data were complete
for the evaluation period (2014–2033), but in some cases,
data on very old individuals were missing for various years
of the initialization period (1994–2013). Whenever this
was the case, the number of individuals in these cohorts
was assumed to be zero (i.e. for Italy 1994–2011: 100+;
Luxembourg: 1994–2005 and 2007–8: 95+, 2006: 100+;
Poland: 1994–2001: 95+, 2002–13: 100+; GB: 1994–2001:
85+; 2002–11: 90+). In the simulations, the initial popula-
tion size was chosen such that the simulated population
reaches exactly 100,000 individuals at the beginning of the
evaluation period (on July 1st, 2014). Births, immigrations,
deaths and changes of the individuals’ risk status occurred
throughout the simulation time, such that the age
Fig. 1 Transmission and immunity dynamics in the simulations: black arrows indicate births and disease progression, red solid arrows indicate
infections, green arrows indicate successful vaccinations, and grey arrows show loss of immunity; dotted red arrows indicate cross-immunization
against a B lineage caused by an infection or vaccination with the other B lineage; vaccinations and infections can also boost existing immunity
(indicated by a “+”); arrows for deaths (which drain each single compartment) were omitted
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Fig. 2 (See legend on next page.)
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distribution of the simulated population corresponded
exactly to the observed or (for future years) the projected
age distribution of the simulated country. Whenever
the number of individuals was predicted to increase
from 1 year to the next one, new individuals of the ap-
propriate age were created during the simulation (inter-
preted as immigrants); such “immigrants” were given
the infection status and the immunologic status of ran-
domly chosen individuals of approximately the same
age [4]. As the vaccination coverage differs for individ-
uals with underlying medical conditions (“at risk” indi-
viduals), we had to consider the risk status of
individuals. A percentage of newborn individuals was
chosen at random to belong to the at risk group. Due
to births, ageing and deaths, the age-dependent percent-
ages at risk continuously changed (i.e. they drifted away
from the values given in Additional file 1: Table S1). To
correct for these deviations, the risk status of randomly
chosen individuals were changed throughout the course of
the simulations.
Contact network
Individuals were interconnected in a contact network
which changed over time. This network was constructed
so that the population statistics of contacts always corre-
sponded to the average number of contacts given by the
country’s contact matrix which was derived from the
contact matrices reported in the POLYMOD study [1].
The original POLYMOD matrices use 15 categories
which usually group individuals in 5-year age classes,
and have an asymmetric structure, i.e. they report con-
tacts in an unidirectional way (in an extreme case this
structure could imply that an individual of a given age
group can contact and infect somebody from another
age group, but cannot be infected by the other person
himself or herself ). We extended the original matrix to a
full 101x101 matrix (to explicitly have contact frequen-
cies for any combination of the simulated 101 age co-
horts), while keeping the sum of contacts in the 5-year
groups identical to the original values. In the simula-
tions, we then applied the extended POLYMOD matrix
such that contacts became bidirectional and that the
contact distribution evolved as the country’s age distri-
bution changes (see Additional file 1 for details).
Infection transmission and natural history
Infective individuals passed on the infection to individ-
uals who were in contact with them, but—due to the
small basic reproduction number of influenza—usually
only a rather small percentage of these contacts were in-
fected. Children have a longer period of infectiousness
and can therefore infect a higher percentage of their con-
tact network. The age-dependent average number of con-
tacts between individuals was determined by the country-
specific POLYMOD matrix [1] as summarized in Table 1.
The infection probability per individual contact per day
was calibrated to be 0.03 for the German model by com-
paring the simulation output with observed data from the
2006/07 German influenza season [4]). In order to be able
to compare different countries, this value was used for all
countries. In the simulations, it was further multiplied by
a seasonal factor which depended on calendar time and
which reached a maximum around Christmas [13]. This
led to seasonal waves which typically peaked in January or
February.
(See figure on previous page.)
Fig. 2 Age distributions of eight European countries. 1st and 2nd column: age distribution of the populations in 1994 and 2033, respectively (the
vertical scales of each pair are identical, but they differ between countries). The white inlays give the number of children (C; 0–19 years), young
adults (A; 20–64 years) and elderly (E; 65+ years) as well as the mean age in the population and the increase of the mean age from 1994 to 2033.
3rd column: growth of the populations (the size in 1994 is set to 100 %)
Table 1 Summary of demographic and contact features of each country averages over the evaluation period 2014–2033
Average age
[years]
Percentage of population Contacts per individual per day
<20 years 20–64 years 65+ years <20 years 20–24 years 65+ years Average
Belgium 41.6 23.0 57.3 19.7 23.2 24.7 13.0 22.0
Finland 43.0 22.1 55.3 22.7 23.6 20.8 8.2 18.5
Germany 46.7 16.9 57.3 25.8 17.1 15.9 9.9 14.5
Great Britain 41.2 23.8 56.6 19.5 26.5 21.8 13.1 21.2
Italy 45.2 18.5 58.2 23.3 50.4 36.2 20.5 35.1
Luxembourg 39.6 23.2 61.3 15.4 38.0 35.8 17.1 33.4
Netherlands 42.8 21.7 57.0 21.3 33.4 27.3 13.0 25.5
Poland 42.7 19.8 60.6 19.6 32.0 33.5 17.7 30.1
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Immunity dynamics
Immunity was lost over time, but could be boosted by
later infections. At random years, new drift variants of
any one of the four influenza types were introduced
which only shared part of their immunologic features
with the previously circulating variant which then was
replaced by the new one. Thus, the occurrence of drift
variants mimicked an additional loss of immunity, leading
to an average duration of immunity of 6 years (A(H1N1)
and B lineages) or 4.5 years (A(H3N2), respectively, in the
absence of boosting events [4]. The two B lineages shared
some cross-immunity: infection with one influenza B virus
could boost the immunity against the other lineage.
Vaccination-derived immunity was lost over time (average
duration 1.8 years [4]), but it could be boosted by sub-
sequent infections; vaccinations could also boost infection-
derived immunity. The vaccine efficacy depends on the age
of the vaccinee [14–16].
Vaccination
Vaccinations were performed annually in October and
November, whereby vaccinees of the previous season
were preferentially re-vaccinated in the new season (see
Additional file 1: Table S1). The vaccination coverage of
all countries, except for the Netherlands, Belgium and
Luxembourg, came from Blank et al. [17], using the
values for 2007, whereby the values for adults and eld-
erly had to be read from their Fig. 2 using the tool “Data
picker” [18]. For the Netherlands, the 2008 vaccination
coverage for the total population came from the web
pages of the Nationaal Programma Grieppreventie [19].
For Belgium, the 2008 vaccination coverage was calcu-
lated from values supplied by the HISIA web pages [20];
to obtain separate values for people with and without
risk, we additionally used the percentage of individuals
“at risk” from Table 6 of [21]. For Luxemburg, no de-
tailed information of the vaccination coverage could be
found. The composition of TIV (which only contains
one B lineage) followed the WHO recommendations of
past years (1994–2014). Despite containing only one B
lineage, TIV vaccination could protect against the missing
B lineage or boost pre-existing immunity against the miss-
ing B lineage, yet the age-dependent vaccine efficacy of
this cross-protection was reduced by 40 % [4]. In some of
the years when a new drift variant occurred, the vaccine
efficacy was reduced against the new variant (vaccine
mismatch).
Scenario analyses
In a first analysis, each country’s demography was used
in combination with its own contact matrix and its own
vaccination coverage (Table 2). To obtain a basic set of
results, the country-specific vaccination coverage was
then replaced by a unified age and risk specific coverage
(i.e. by an arbitrarily chosen coverage which was close to
the country-specific coverage of most countries): for people
without risk status, the vaccination coverage was assumed
to be 20 % (0–2 years), 10 % (3–10), 5 % (11–15), 10 %
(16–59) and 50 % (60+), respectively; for people with risk
status, it was 30 % (0–59) and 70 % (60+), respectively. In
two further analyses, we explored how the contact struc-
ture and the demography influenced the results by either
modifying the contact matrix or the demography while
keeping everything else constant.
Reporting
Each simulation was set up to have a population size of
100,000 individuals at the start of the evaluation period.
Due to demographic turnover, the simulated number of
individuals in earlier years (i.e. in the initialization period)
and in later years differed from 100,000. The average an-
nual incidence of influenza infections per 100,000 individ-
uals was calculated by (1) determining the number of
infections projected by the model for each evaluation year
of each simulation, (2) transforming these numbers into
incidence values per 100,000 individuals, (3) averaging the
annual incidence values of each simulation over the 20
evaluation years, and (4) by calculating the mean of these
values over 1000 simulations. The country-specific num-
ber of prevented infections was calculated as the differ-
ence between the mean annual incidence values of 1000
simulations without vaccination and with unified vac-
cination coverage. The country-specific vaccination effect
was then given as the percentage of prevented infections.
Results
Demographic differences
The age distributions of the eight countries differed widely
and they underwent rather extreme changes between the
start of the initialization phase (1994) and the end of the
evaluation period (2033; Fig. 2), e.g. Poland changed from
being the country with by far the highest percentage of chil-
dren and juveniles (31.8 % below 20 years of age in 1994)
to a country which ranked among the lowest (18.4 % in
2033), whereas its percentage of elderly (65+) more than
doubled. In each of the eight countries, the population’s
mean age increased during the simulation (by at least
1.9 years in Luxembourg up to 10.7 years in Poland). In
some countries like Germany, the size of the population
declined whereas in others it grew. At least part of this
growth must be explained by immigration as is the case
for Luxembourg which is predicted to grow by over 100 %
until 2033, yet whose age distribution stays nearly con-
stant. The demography of Finland was used in simulations
where the same demography was used for every country
and where only the contact matrix was varied because its
demographic features (percentage of children, average age,
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annual growth rate) were close to the median of the coun-
ties depicted in Fig. 2.
Differences in contact distributions
The countries also differed strongly by their numbers of
contacts per individual and by the age distribution of
these contacts: the 1st column of Fig. 3 shows the results
of the POLYMOD study [1]; black sections denote con-
tacts with children and juveniles (0–19 years), dark grey
ones contacts with young adults (20–64 years) and light
grey ones contacts with elderly (65+ years). The contact
matrix of Belgium was used in simulations where the
same matrix was used for every country and where only
the demography was varied because this contact matrix
appeared to lie between the matrices of the matrices of
all the counties depicted in Fig. 3. In the simulation tool
4Flu, the contacts depicted in the first column are inter-
preted as “outgoing” contacts which are initiated by the
individuals whose ages are given on the horizontal axis.
To obtain the age distribution of all contacts in the
population (shown in the 3rd column of Fig. 3), the
contacts per individual must be combined with the age
distribution of the population (2nd column of Fig. 3;
see Additional file 1 and [4] for more explanations).
Germany had by far the lowest average number of con-
tacts less than half of the value of Italy, which was the
other extreme. The 4th column of Fig. 3 summarizes the
contact distribution which prevailed during the evaluation
period of the simulations (figure areas are proportional to
population size and arrow thickness is proportional to
number of contacts): young adults (A) form the largest
section of the population; the vast majority of contacts are
among young adults, followed by contacts among children
(C) and between children and adults. The epidemiological
importance of children is further enhanced by the fact that
they enter the population susceptible (at least after having
passed through a short-term period of material protec-
tion) and that they are assumed to have a longer period of
infectiousness (Additional file 1: Table S1). Although
elderly (E) also form a big segment of the population,
contacts among them or between elderly and others are
comparatively scarce.
Results without vaccination
Simulation results without vaccination for the annual
influenza infection incidence of the eight countries
Table 2 Vaccination coverage in the different countriesa
Country Group Vaccination coverage (from age to age) [%] Ref.
Belgium not at risk 1.7 (0–17), 6.5 (18–24), 10.1 (25–34), 14.8 (35–44),
18.4 (45–54), 32.5 (55–64), 60.2 (65–74), 72.6 (75+)
[16, 17]
at risk 5.0 (0–17), 15.3 (18–24), 13.0 (25–34), 15.6 (35–44),
25.2 (45–54), 38.2 (55–64), 60.2 (65–74), 72.6 (75+)
Finland not at risk 36.2 (0–2), 6.1 (3–6), 5.1 (7–10), 2.6 (11–14),
6.0 (15–64), 46.5 (65+)
[13]
at risk 24.0 (0–64), 64.6 (65+)
Germany not at risk 19.2 (0–2), 22.4 (3–6), 23.6 (7–10), 11.0 (11–13),
14.4 (14–64), 48.8 (65+)
[13]
at risk 26.8 (0–64), 76.3 (65+)
Great Britain not at risk 13.4 (0–2), 7.1 (3–6), 4.3 (7–10), 3.0 (11–15),
10.6 (16–64), 70.2 (65+)
[13]
at risk 56.4 (0–64), 91.6 (65+)
Italy not at risk 24.5 (0–2), 17.9 (3–6), 14.7 (7–10), 8.3 (11–13),
12.8 (14–64), 56.3 (65+)
[13]
at risk 42.1 (0–64), 72.7 (65+)
Netherlands All 2.0 (0–4), 4.2 (5–9), 4.9 (10–14), 5.0 (15–19),
4.1 (20–24), 4.1 (25–29), 4.7 (30–34), 5.6 (35–39),
8.5 (40–44), 11.2 (45–49), 16.1 (50–54), 30.6 (55–59),
63.9 (60–64), 75.3 (65–69), 81.3 (70–74), 86.1 (75–79),
85.8 (80–84), 85.5 (85–89), 82.7 (90–94), 77.2 (95+)
[15]
Poland not at risk 10.0 (0–2), 13.0 (3–6), 10.7 (7–10), 5.2 (11–14),
7.5 (15–64), 14.0 (65+)
[13]
at risk 11.6 (0–64), 17.1 (65+)
Unified vaccination
coverage
not at risk 20.0 (0–2, 10.0 (3–10), 5.0 (11–15), 10.0 (16–59),
50.0 (60+)
at risk 30.0 (0–59), 70.0 (60+)
abased on data from 2007 to 2008; sufficient information on Luxembourg was not available
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Fig. 3 (See legend on next page.)
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differed considerably (Fig. 4a), ranging from 20,984 infec-
tions per 100,000 per year in Germany to 31,322 infections
in Italy. The deviation of the individual countries from
their common mean value was quite high (coefficient of
variation CV= 11.8 %). Although clearly visible, the differ-
ences in inter-country variances were not statistically sig-
nificant which presumably was due to the small number of
countries on which these comparisons were based (Brown-
Forsythe test; p > 0.05).
Results of scenario analyses
To examine the influence of the demography on infection
incidence, we ran simulations where the countries’ dem-
ography was replaced by the Finish demography (Fig. 4b).
(See figure on previous page.)
Fig. 3 Distribution of contacts for eight countries. 1st column: contacts per individual per day according to the POLYMOD study [5]. Second column:
age distributions using the age classes of the POLYMOD study (averages of representative population samples of 1000 individuals per year for the
period from 2014 to 2033). 3rd column: total number of contacts per day in a population of 1000 individuals with the age distributions of the 2nd
column (combining contacts initiated by the age group and directed to the age group by others; see text for further explanations). Color coding of
the bars in the 1st and 3rd column: black = contact with children and juveniles (0–19 years); dark grey: contacts with young adults (20–64 years); light
grey: contacts with elderly (65+ years). 4th column: contacts among children (C), young adults (A) and elderly (E); thickness of arrows are proportional
to the numbers of contacts (numbers denote daily contacts in a population with a total size of 1000 individuals)
Fig. 4 Simulation results for the annual incidence of influenza infections per 100,000 individuals without vaccination in eight countries (black:
children (C) 0–17 years, dark grey: adults (A) 18–64 years; light grey: elderly (E) 65+ years). a original combination of each country’s demography and
contact matrix (coefficient of variation [CV] for C: 17.8 %, A: 12.3 %, E: 20.5 %, all: 11.8 %); b combining the Finnish demography with each country’s
contact matrix (CV for C: 6.5 %, A: 7.0 %, E: 16.5 %, all: 7.8 %); c combining each country’s demography with the Belgian contact matrix (CV for C:
15.3 %, A: 4.1 %, E: 14.6 %, all: 3.2 %). Comparing the variability in the three graphs (either by age group or for the total), using Brown-Forsythe-Test,
yielded non-significant results (p > 0.05). For each set of simulation parameters, averages of 1000 simulations running for 20 years were calculated
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This had a unifying effect on the results (CV = 7.8 %),
much of which was due to infection incidence in children
and juveniles 0–19 years of age (whose CV was reduced
from 17.8 to 6.5 %) and adults 20–64 years of age (whose
CV was reduced from 12.3 to 7.0 %), indicating that these
age groups contributed more to the inter-country variabil-
ity of incidence than the elderly (whose CV only changed
from 20.5 to 16.5 %). To also examine the influence of the
contact matrix on infection incidence, we ran simulations
where each country’s contact matrix was replaced by the
Belgian one (Fig. 4c). The unifying effect of replacing the
contact matrix was even stronger (CV = 3.2 %) than that
of using the same demography. The unifying effect was
most pronounced in adults (whose CV is reduced from
12.3 to 4.1 %) and much less in Children (whose CV was
reduced from 17.8 to 15.3 %) and elderly (whose CV was
reduced from 20.5 to 14.6 %).
Prevented infections
If each country’s own vaccination coverage was used in
the simulations, QIV vaccination prevented from 1758
infections (in Poland) to 7720 infections (in Germany;
Fig. 5a; Table 3). The CV of the inter-country variability
was 41.4 %. Replacing the country-specific vaccination
coverage by a unified vaccination coverage (Fig. 5b) re-
duced the variability to CV = 27.9 %. To allow for a better
comparison of countries and to also include Luxembourg
(for which the original vaccination coverage was missing),
Fig. 5 Simulation results for the number of influenza infections which are annually prevented by QIV vaccination in a population of 100,000
individuals (black: children (C) 0–17 years, dark grey: adults (A) 18–64 years; dark grey: elderly (E) 65+ years). a combining each country’s specific
vaccination coverage with its demography and contact matrix (coefficient of variation [CV] for C: 65.2 %, A: 47.7 %, E: 36.2 %, all: 41.4 %); b–d
using the same unified vaccination coverage for all countries: b combining each country’s demography with its contact matrix (CV for C: 31.1 %,
A: 34.9 %, E: 22.1 %, all: 27.9 %); c combining the Finnish demography with each country’s contact matrix (CV for C: 30.1 %, A: 30.0 %, E: 14.2 %,
all: 22.6 %); d combining each country’s demography with the Belgian contact matrix (CV for C: 8.6 %, A: 7.2 %, E: 17.9 %, all: 8.0 %). Comparing
the variability in the four graphs (either by age group or for the total), using Brown-Forsythe-Test, yielded non-significant results (p > 0.05). For
each set of simulation parameters, differences are based on 1000 simulations with vaccination and 1000 simulations without vaccination whereby
each simulation ran for 20 years
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we used the results with unified vaccination coverage in
the following analyses. Replacing each country’s contact
matrix by the Belgian one (Fig. 5d) again had a large unify-
ing effect on the absolute number of vaccine prevented in-
fections (CV reduced to 8.0 %). The additional unifying
effect was most pronounced in children and juveniles
(whose CV was reduced from 31.1 to 8.6 %) and younger
adults (whose CV was reduced from 34.9 to 7.2 %), but
much less in elderly (whose CV was reduced from 22.1 to
17.9 %). Applying the Finish demography for all countries
hardly led to any reduction in overall variability of vaccine
effects (Fig. 5c; CV = 22.6 %).
Discussion
Measuring epidemiologic variability among countries al-
lows investigation of the influence of the contact matrix
and demography on infection incidence and vaccine
prevented infections. When using the same contact
matrix for each country, overall variability of infection
incidence was greatly reduced. In contrast, if the same
age-distribution was used for each country, this had
only a minor harmonizing effect. Thus, the contact matrix
was the most important factor which determined differ-
ences in country-specific infection incidence. The impact
of the contact matrix on vaccine prevented infections was
particular striking in children, juveniles and young adults
which may be due to the high inter-country differences in
the number of contacts of young people (Fig. 3). Thus,
when applying the same vaccination strategy in countries
with different contact matrices, the number of vaccine
prevented infections may differ greatly—particularly for
the younger age groups—even if exactly the same age and
risk group specific vaccination coverage is used.
As is the case with every modeling study, we had to
make some simplifying assumptions. We used the same
transmission probability irrespective of the country.
Although the same contact questionnaire was used in
all POLYMOD countries, contacts among people or
reporting could be different between countries. For the
sake of examining the influence of contact matrix and
age-distribution on the effects of influenza vaccination,
it seems justified to keep as many parameters constant
as possible, but for a more in-depth evaluation of the
benefits of influenza vaccination, it may be warranted
to separately calibrate the transmission probability and
to use as many country-specific parameter values as
possible. We used the same age-dependent percentage
of individuals at risk for all countries, whereas the def-
inition of who is regarded to be “at risk” may differ be-
tween countries. This should not have a large impact
on the results, as the values for Belgium and for the
Netherlands tend to be rather similar to the German
ones [21–23]. The results for Germany reported in this
paper slightly differ from the previously reported ones
[4]. Reasons for this are (a) the initialization period and
the evaluation period start 1 year later than in the previ-
ous paper, (b) the composition of TIV could now be fixed
until 2014, and (c) we have extended the number of con-
tact matrix age groups (but this had negligible impact on
the results; see Additional file 1 for details). Furthermore,
the results in the published paper were given for 0.1 % of
the German population whereas here we report results
per 100,000 individuals to facilitate comparisons between
countries.
Conclusions
Taken together, the country’s contact matrix and to a
much lesser degree the demography influence infection
incidence and vaccine effects. The effects vary by age
group; for vaccine effects, contact matrices affect more
Table 3 Mean number of infections per year per 100,000 inhabitants
Country Original demography and contact matrix Demography of Finland Contact matrix of Belgium
No vacc. Original vacc. Unified vacc. No vacc. Unified vacc. No vacc. Unified vacc.
Belgium 29,194 24,391 (−16.5 %) 24,301 (−16.8 %) 28,799 23,566 (−18.2 %) 29,194 24,301 (−16.8 %)
Finland 26,675 23,002 (−13.8 %) 22,270 (−16.5 %) 26,675 22,270 (−16.5 %) 28,799 23,566 (−18.2 %)
Germany 20,984 13,263 (−36.8 %) 14,795 (−29.5 %) 24,893 19,174 (−23.0 %) 27,249 21,327 (−21.7 %)
Great Britain 28,952 23,617 (−18.4 %) 24,480 (−15.4 %) 27,975 23,121 (−17.4 %) 29,474 24,552 (−16.7 %)
Italy 31,322 27,643 (−11.7 %) 28,238 (−9.8 %) 31,997 28,880 (−9.7 %) 27,584 22,135 (−19.8 %)
Luxembourg 31,216 n.a. 28,588 (−8.4 %) 30,256 26,913 (−11.0 %) 29,970 25,409 (−15.2 %)
Netherlands 29,351 25,319 (−13.7 %) 25,562 (−12.9 %) 29,135 25,437 (−12.7 %) 28,507 23,339 (−18.1 %)
Poland 30,056 28,297 (−5.9 %) 26,750 (−11.0 %) 30,167 26,641 (−11.7 %) 28,498 23,491 (−17.6 %)
CV 11.8 % 21.1 % 18.1 % 7.8 % 12.6 % 3.2 % 5.6 %
Mean number of infections per year per 100,000 inhabitants without or with vaccination, using either the country’s own combination of contact matrix and
demography, or replacing the country’s contact matrix by the Belgian one, or replacing the country’s demography by the Finish one; “Original vacc.” denotes the
vaccination coverage which actually is used in the different countries (unknown for Luxembourg); “Unified vacc.” uses the same vaccination strategy in every
country (see text for details); trivalent influenza vaccine (TIV) is used before 2014; tetravalent influenza vaccine (QIV) is used from 2014 to 2033. Each cell gives the
average result of 1000 simulations running from 2014 to 2033
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the younger and demography more the older age groups.
Projecting simulation results from one country to an-
other can, therefore, lead to erroneous results.
Additional file
Additional file 1: The online available file “Supporting_Material_4Flu.pdf”
explains (1) the extension and smoothing of the original POLYMOD matrix
(2) the translation of the resulting matrix into a contact network (3) the
occurrence of super-spreaders in the simulation tool 4Flu (PDF 930 kb)
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